Business Wire

Genesis Q1 2022 Report Reflects Another Strong Quarter Amid Market Uncertainty

29.4.2022 16:15:00 EEST | Business Wire | Press release

Share

Genesis, a digital asset industry pioneer and digital currency prime brokerage, today released its Q1 2022 Market Observations Report, highlighting major trends across institutional digital asset markets. The report provides a breakdown of Genesis’ lending, derivatives, spot, and custody activities across Q1 2022, along with in-depth insight from the Genesis lending and derivatives desks on trends such as the growing adoption of permissioned DeFi protocols, the gradual institutionalization in debt markets and the continued growing interest from the traditional financial community in stablecoin derivatives.

The first quarter was characterized by Genesis’ notable growth across most of its operations – including another record quarter in derivatives trading activity – even against the backdrop of lower overall crypto market volumes and high levels of uncertainty throughout most asset types. Highlights during the quarter include the following:

  • In Q1 2022, the USD amount of active loans outstanding grew to $14.6 billion against declining prices, a level 17% higher than at the end of the previous quarter, and 62% higher than at the end of Q1 2021.
  • As of March 31, cumulative loan originations had reached $195 billion.
  • The notional volume traded by the derivatives desk in Q1 reached $27.8 billion, up 33% from Q4, inclusive of negotiated block- and exchange- traded futures.
  • Assets under custody increased by 23% over Q1.
  • The USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% vs Q4 2022.
  • Genesis’ headcount increased 22% over the quarter to reach 208 employees across three continents.

“Institutions continue to develop their crypto strategies and strengthen their understanding of this industry, even amid the market uncertainty that has marked the start to this year,” said Michael Moro, CEO of Genesis. “As we continue to deepen engagement with our clients across Genesis’ wide range of products, we are committed to further expanding our market share and delivering innovative strategies for clients to access this growing asset class.”

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity, with over $27.8 billion in notional value traded globally. This figure includes bilateral OTC, negotiated block futures trades and exchange-traded volumes, representing 33% quarter-on-quarter growth. In Q1, Genesis was also #1 in market share for blocked BTC and ETH Deribit-cleared derivatives via Paradigm with over $6.6 billion transacted1. The firm also printed the first ever ETH and BTC Micro options trades on the CME in March. Additionally, the Genesis derivatives desk traded 61 different assets in the first quarter, with $4.7 billion notional traded in altcoin derivatives – Genesis’ highest quarterly total yet as it continues to prove its ability to help clients hedge and take directional positions in even the most esoteric of markets.

The Genesis spot desk traded over $11.4 billion in volume in Q1, with the continuing trend toward greater diversification of assets. BTC comprised 48% of the traded volume, in line with last quarter, while ETH saw a drop from 33% to 23% of total traded volume in Q1. The Genesis spot desk also saw a notable increase in activity across assets such as LUNA, SOL, AVAX, ZEC, LINK, ATOM and GALA.

Crypto Lending

Despite a market environment faced with many uncertainties, as valuations across all crypto assets nearly halved from November peaks, the Genesis lending desk originated over $44.3 billion in loans in Q1 2022, bringing cumulative originations since inception in March 2018 to $195 billion. Active loans outstanding also climbed to $14.6 billion to close the quarter, up 17% from the end of 2021.

The strong level of activity Genesis saw in Q1 – despite the weak market environment – was mainly due to organic volume driven by new institutions entering the industry and by increasing demand for cash loans, which allowed Genesis to capitalize on its core competitive strengths as a leading digital asset prime broker.

Custody

Assets under custody increased by 23% quarter-on-quarter, while the USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% over the same period. This comes as Genesis continues to integrate its lending and trading desks more tightly into its SOC 2 Type 1-audited and FCA-registered custodian.

The number of customers onboarded to Genesis Custody also increased by 36% over the quarter, driven mainly by large public and private mining companies, venture capital firms and other traditional asset managers on a global level, following Genesis’ FCA registration and the roll out of its 24/5 support.

The Genesis Q1 2022 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q1 2022 Market Observations Report, click here.

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG), one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

____________________________
1 Per Paradigm statistics as of April 28, 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marc Yaklofsky
press@genesistrading.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye